<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100149</url>
  </required_header>
  <id_info>
    <org_study_id>BP39529</org_study_id>
    <secondary_id>2017-000087-15</secondary_id>
    <nct_id>NCT03100149</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy of RO7046015 in Participants With Early Parkinson's Disease</brief_title>
  <acronym>PASADENA</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants With Early Parkinson's Disease With a 52-Week Blinded Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prothena Biosciences Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate
      the efficacy of intravenous RO7046015 versus placebo over 52 weeks in participants with early
      Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B)
      inhibitors since baseline. The study will consist of 2 parts: a 52-week, double-blind,
      placebo-controlled treatment period (Part 1) after which eligible participants will continue
      into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part
      2).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2017</start_date>
  <completion_date type="Anticipated">June 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score (Sum of Parts I, II, and III) at Week 52</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dopamine Transporter Imaging With Single Photon Emission Computed Tomography (DaT-SPECT) Signal at Week 52</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the MDS-UPDRS Motor Subscale (Part III) Score</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI-I) Score at Weeks 24 and 52</measure>
    <time_frame>Week 24 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) Score at Weeks 24 and 52</measure>
    <time_frame>Week 24 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Start of Dopaminergic Symptomatic Treatment</measure>
    <time_frame>From Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)</measure>
    <time_frame>From Day 1 to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Drug Antibodies (ADAs) Against RO7046015</measure>
    <time_frame>Baseline, Pre-dose (0 hours) on Weeks 4, 20, 36, 52, 56, 68, 80, and 104; at early termination (up to Week 104), and follow-up (12 weeks after last dose up to Week 116)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) of RO7046015</measure>
    <time_frame>Predose (0 hours) and end of infusion (infusion length=2 hours or less) on Day 1, Weeks 4, 20, 36, 52, 56, 68, 80, and 104; at Day 7, Day 14, early termination (up to Week 104), and follow-up (12 weeks after last dose up to Week 116)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of RO7046015</measure>
    <time_frame>Predose (0 hours) and end of infusion (infusion length=2 hours or less) on Day 1, Weeks 4, 20, 36, 52, 56, 68, 80, and 104; at Day 7, Day 14, early termination (up to Week 104), and follow-up (12 weeks after last dose up to Week 116)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve (AUC) of RO7046015</measure>
    <time_frame>Predose (0 hours) and end of infusion (infusion length=2 hours or less) on Day 1, Weeks 4, 20, 36, 52, 56, 68, 80, and 104; at Day 7, Day 14, early termination (up to Week 104), and follow-up (12 weeks after last dose up to Week 116)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of RO7046015</measure>
    <time_frame>Predose (0 hours) and end of infusion (infusion length=2 hours or less) on Day 1, Weeks 4, 20, 36, 52, 56, 68, 80, and 104; at Day 7, Day 14, early termination (up to Week 104), and follow-up (12 weeks after last dose up to Week 116)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Serum Trough Concentration (Ctrough) of RO7046015</measure>
    <time_frame>Predose (0 hours) and end of infusion (infusion length=2 hours or less) on Day 1, Weeks 4, 20, 36, 52, 56, 68, 80, and 104; at Day 7, Day 14, early termination (up to Week 104), and follow-up (12 weeks after last dose up to Week 116)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Part 1: RO7046015 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7046015 at high dose level as intravenous infusion every 4 weeks (Q4W) up to 52 weeks in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: RO7046015 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7046015 at low dose level as intravenous infusion Q4W up to 52 weeks in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo as intravenous infusion Q4W up to 52 weeks in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: RO7046015 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 RO7046015 high dose group participants and placebo group participants randomized to high dose level will receive RO7046015 at high dose level as intravenous infusion Q4W for additional 52 weeks in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: RO7046015 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 RO7046015 low dose group participants and placebo group participants randomized to low dose level will receive RO7046015 at low dose level as intravenous infusion Q4W for additional 52 weeks in Part 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7046015</intervention_name>
    <description>RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (&gt;/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (&lt;) 65 kg.</description>
    <arm_group_label>Part 1: RO7046015 High Dose</arm_group_label>
    <arm_group_label>Part 2: RO7046015 High Dose</arm_group_label>
    <other_name>PRX002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7046015</intervention_name>
    <description>RO7046015 will be administered at dose of 1500 mg to all participants in the indicated arm.</description>
    <arm_group_label>Part 1: RO7046015 Low Dose</arm_group_label>
    <arm_group_label>Part 2: RO7046015 Low Dose</arm_group_label>
    <other_name>PRX002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>RO7046015 placebo will be administered to all participants in the indicated arm.</description>
    <arm_group_label>Part1: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic PD with bradykinesia plus one of the other cardinal signs of PD (resting
             tremor, rigidity) being present, without any other known or suspected cause of PD
             untreated or treated with MAO-B inhibitor

          -  Body weight range between: &gt;/=45 kg/ 99 pounds (lbs) and less than or equal to (&lt;/=)
             110 kg/242 lbs

          -  Body mass index (BMI) of 18 to 34 kilograms per meter-squared (kg/m^2)

          -  A diagnosis of PD for 2 years or less at screening

          -  Hoehn and Yahr Stage I or II

          -  A screening brain DaT-SPECT consistent with PD (central reading)

          -  Clinical status does not require dopaminergic PD medication and is not expected to
             require dopaminergic treatment within 52 weeks from baseline

          -  If presently being treated for PD, a stable dose of MAO-B inhibitor (rasagiline or
             selegiline) for at least 90 days prior to baseline and not expected to change within
             52 weeks

          -  For women of childbearing potential: use of highly effective contraceptive methods
             (that result in a failure rate of &lt;1 percent [%] per year) during the treatment period
             and for at least 30 days (or longer if required by local regulations) after the last
             dose of study drug

          -  For men with female partners of childbearing potential or pregnant female partners,
             must use a condom during the treatment period and for at least 30 days (or longer if
             required by local regulations) after the last dose of study drug to avoid exposing the
             embryo. Men must refrain from donating sperm during this same period. The female
             partners should use a contraception method with a failure rate of &lt;1% per year during
             the treatment period and for at least 30 days (or longer if required by local
             regulations) after the last dose of study drug

        Exclusion Criteria:

          -  Clinical signs or past medical history indicating a Parkinson syndrome other than
             idiopathic PD, including but not limited to, progressive supranuclear gaze palsy,
             multiple system atrophy, drug-induced parkinsonism, essential tremor, primary dystonia

          -  Known carriers of certain familial PD genes (as specified in study protocol)

          -  History of PD related freezing episodes or falls

          -  A diagnosis of a significant CNS disease other than Parkinson's disease; history of
             repeated head injury; history of epilepsy or seizure disorder other than febrile
             seizures as a child

          -  Mini Mental State Examination (MMSE) &lt;/=25

          -  Reside in a nursing home or assisted care facility

          -  History of or screening brain magnetic resonance imaging (MRI) scan indicative of
             clinically significant abnormality

          -  Concomitant disease or condition that could interfere with, or treatment of which
             might interfere with, the conduct of the study, or that would, in the opinion of the
             Investigator, pose an unacceptable risk to the participant in this study or interfere
             with the participant's ability to comply with study procedures or abide by study
             restrictions, or with the ability to interpret safety data

          -  Any significant cardiovascular condition

          -  Any significant laboratory abnormality

          -  Lactating women

          -  Prior treatment with dopaminergic medication (for example, levodopa or a dopaminergic
             agonist) with no clinical treatment response or a clinical treatment response
             inconsistent with PD

          -  Use of any of the following: catechol-O-methyl transferase (COMT) inhibitors
             (entacapone, tolcapone), amantadine or anticholinergics, or dopaminergic medication
             (levodopa and both ergot and non-ergot [pramipexole, ropinirole, rotigotine] dopamine
             agonists) for more than a total of 60 days or within 60 days of baseline

          -  Anti-epileptic medication for non-seizure-related treatment which has not remained
             stable for at least 60 days prior to baseline

          -  Anti-depressant or anxiolytic use that has not remained stable for at least 90 days
             prior to baseline. The use of fluoxetine and fluvoxamine is not permitted. For
             patients treated with a MAO-B inhibitor and a selective serotonin reuptake
             inhibitor/serotonin and norepinephrine reuptake inhibitor (SSRI/SNRI), a 6-month
             period of stable and tolerated dosing before baseline is required.

          -  Use of any of the following within 90 days prior to baseline: antipsychotics
             (including clozapine and olanzapine), metoclopramide, alpha methyldopa, clozapine,
             olanzapine, flunarizine, amoxapine, amphetamine derivatives, reserpine, bupropion,
             buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine,
             phentermine, phenylpropanolamine, and modafinil

          -  Participated in an investigational drug or device study including prior treatment of
             PD involving intracranial surgery or implantation of a device

          -  Any prior treatment with an investigational PD-related vaccine (including active
             immunization or passive immunotherapy with monoclonal antibodies).

          -  Prior participation in any RO7046015 or PRX002 study

          -  Receipt of an investigational product or device, or participation in a drug research
             study within a period of 30 days (or 5 half-lives of the drug, whichever is longer)
             before baseline

          -  Receipt of a monoclonal antibody or an investigational immunomodulator within 180 days
             (or 5 half-lives, whichever is longer) before baseline

          -  Immunomodulating drugs within 30 days prior to baseline

          -  Allergy to any of the components of RO7046015 or a known hypersensitivity or an
             Infusion-related reaction (IRR) to the administration of any other monoclonal antibody

          -  Any contraindications to obtaining a brain MRI. Patients with a hypersensitivity to
             iodine may receive an alternative thyroid blocking agent.

          -  For participants consenting to provide optional cerebrospinal fluid (CSF) samples by
             lumbar puncture (LP): LP will only be performed if the participant does not have any
             contraindication to undergoing an LP

          -  Donation of blood over 500 milliliters (mL) within three months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Reference Study ID Number: BP39529 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S.)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Medical Information:</last_name>
    <email>global.medical_information@roche.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uab Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barrow Neurology Clinics; Movement Disorders Program</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC Keck Medical Center of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Associated Neurologists of Southern CT PC</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Molecular Neurolmaging</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Compass Research East, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USF Parkinsons Disease and Movement Disorders Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>20742</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Medical Group</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo; Center for Brain Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science Uni</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UNIVERSITY of PENNSYLVANIA</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor College</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck; Universitätsklinik für Neuroradiologie</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Pays dAix</name>
      <address>
        <city>Aix En Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Chu Amiens Picardie - Site Sud</name>
      <address>
        <city>Amiens</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Gabriel Montpied</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor; Service de Neurologie</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Michallon - Centre d'Investigation Clinique; Unité de Pharmacologie Clinique - Inserm</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nice Hopital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie-Salpetriere APHP</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Rouen Charles Nicolle; Centre Expert Parkinson Hôpitaux de Rouen</name>
      <address>
        <city>Rouen cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hopital Laennec</name>
      <address>
        <city>St Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CIC - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik fur Neurologie; Campus Mittev</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heinrich-Heine Universitätsklinik Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paracelsus Elena Klinik Kassel</name>
      <address>
        <city>Kassel</city>
        <zip>34128</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurology UKSH Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Neurologie Universitätsklinikum</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Philipps Universität Marburg ; Klinik für Neurologie</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaettsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm; Klinik für Neurologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General de Catalunya</name>
      <address>
        <city>San Cugat Del Valles</city>
        <state>Barcelona</state>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Hospital de Alcorcon</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona/iruña</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial.</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa; Servicio de Neurologia</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pasadenastudy.com</url>
    <description>Pasadenastudy.com provides information about the Roche clinical trial NCT03100149 and molecule being investigated in Parkinson's Disease</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

